{"mcpName":"station__algovigilance__microgram-fda-sponsor-ind-safety","slug":"algovigilance__microgram-fda-sponsor-ind-safety","label":"Microgram: fda-sponsor-ind-safety","description":"FDA sponsor IND safety reporting assessment: determines reporting obligation from event characteristics per FDA Guidance 'Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and BA/BE Studies' (2025) and 21 CFR 312.32","domainSlug":"algovigilance","pvRelevance":"pv-core","backend":"native","agentMetadata":{"idempotent":true,"read_only":true,"expected_latency_ms":null,"cost_tokens_estimate":null,"pipes_to":null},"inputSchema":{"type":"object","properties":{"suspected_adverse_reaction":{"type":"boolean","description":"Whether there is a reasonable possibility the drug caused the event"},"serious":{"type":"boolean","description":"Whether the event meets serious criteria per 21 CFR 312.32(a)"},"unexpected":{"type":"boolean","description":"Whether the event is not listed in the Investigator Brochure"},"fatal_or_life_threatening":{"type":"boolean","description":"Whether the event resulted in death or was life-threatening"},"study_type":{"type":"string","description":"Type of study: ind, ba_be, ba_be_ind_exempt"}},"required":["suspected_adverse_reaction","serious","unexpected"],"additionalProperties":false},"example":null,"taxonomy":{"rank":{"domain":"Substrata","kingdom":"Constructa","phylum":"Configa","class":"station-config","order":"algovigilance","family":"mcp-tool-config"},"characteristics":{"substrate":"config","domain":"pv","lifecycle":"continuous","stateful":false,"persistence":"none","authority":"read","compounding":"producer","io_input":"agent-request","io_output":"tool-response"}},"_links":{"html":"/tools/algovigilance__microgram-fda-sponsor-ind-safety","markdown":"/tools/algovigilance__microgram-fda-sponsor-ind-safety/raw.md","invoke":"/api/mcp","catalog":"/api/mcp"}}